Summary: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections (LRTIs) in children, especially those with cancer. Data on RSV infections in this vulnerable population is limited. We conducted a retrospective study of all RSV infections in children with cancer from 1998 to 2009 to determine characteristics and outcomes of these infections, identify risk factors for LRTI and mortality, and the effect of antiviral therapy on these outcomes. We identified 59 patients with a median age of 5 years; 53% had hematologic malignancy, 32% were hematopoietic stem cell transplant recipients, 39% had received corticosteroids, and 76% cytotoxic chemotherapy within 1 month before RSV infection. LRTI developed in 22 (37%) patients with a trend of higher rate in males (odds ratio = 2.57 [0.86-7.62 R espiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection (LRTI) in infants. 1 In healthy children and infants, it usually causes upper respiratory tract infection (URTI); however, it may present as bronchiolitis or pneumonia in 25% to 40% of patients, 2 with a mortality rate of <0.5%. 3 Children with cancer who are undergoing chemotherapy or have undergone hematopoietic stem cell transplantation (HSCT) represent a vulnerable population because of chemotherapy-induced myelosuppression, impaired T-cell immune response, and persistent lymphopenia. 4 In the absence of RSV-specific therapy administration, progression to LRTI has been observed in about 50% of children with cancer who have undergone HSCT, 5 and RSV-associated mortality rates of up to 10%. A recent study followed high-risk pediatric patients, including 16 cancer patients, and noticed 12.5% mortality among them following RSV infections. 6 Therapeutic options for RSV infection are limited and include the antiviral drug ribavirin, immunomodulators such as intravenous polyclonal immunoglobulin (IVIG) and RSV-IVIG, and RSV-specific monoclonal antibody palivizumab. Although aerosolized ribavirin (AR) alone has been shown to be effective in preventing the appearance of any symptoms in asymptomatic RSV-positive pediatric HSCT patients, 5 the use of AR alone to treat infants with RSV-LRTI is not supported by evidence of significant benefit. However, previous studies of ribavirin therapy for RSV-LRTI in children lack sufficient power to rule out a potential reduction in mortality rate or respiratory deterioration. 7 Prospective and retrospective studies of RSV-IVIG and palivizumab alone or in combination with ribavirin have reported varying degrees of efficacy. In 2000, DeVincenzo et al 8 compared the efficacy of ribavirin alone with that of RSV-IVIG in 11 children with cancer who had undergone bone marrow transplant and had RSV-LRTI. They showed a 3-to 30-fold increase of the serum RSV neutralizing titers 24 hours after RSV-IVIG infusion and found that RSV-IVIG was more effective than ribavirin treatment in reducing the mortality rate in those patients. 8 And recently, Anak et al 4 showed the importance of early diagnosis and treatment of RSV infection in children with cancer and demonstrated that IVIG plus ribavirin was effective in reducing RSV-related mortality in these patients.
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The objective of this study was to determine the clinical characteristics and outcomes of RSV infections in children with cancer. We also aimed to examine whether RSV-specific therapy is associated with a reduced rate of progression to RSV-LRTI and reduced RSV-related mortality in children with cancer. We present the results of children with cancer who were diagnosed with RSV infections at The University of Texas MD Anderson Cancer Center over a period of 12 years.
METHODS

Study Population
We searched the Infection Control database to identify all children with cancer (up to and including 18 y of age) who had been diagnosed with RSV infection from January 1, 1998, to December 31, 2009. The MD Anderson Institutional Review Board approved this study and waiver of consent was granted.
Diagnosis of RSV Infection
Samples were collected from patients with respiratory symptoms by using nasopharyngeal washes, throat swabs, and/or bronchoalveolar lavages. RSV was diagnosed with direct fluorescent antigen (DFA) testing on the obtained sample and/or by viral culture using the shell vial culture technique as previously described. 9, 10 Definitions RSV URTI was defined as the onset of rhinorrhea, nasal or sinus congestion, otitis media, pharyngitis, and/or cough with or without expectoration and with a positive RSV DFA and/or viral culture result from a nasal wash. RSV-LRTI was defined as clinical signs and symptoms compatible with RSV bronchiolitis or pneumonia (cough, hypoxia, and/or fever with new or changing pulmonary infiltrates as documented by a chest x-ray and/or computed tomography of the chest) and a positive RSV DFA and/or viral culture result from a respiratory sample (nasal wash, throat swab, endotracheal tube aspirate, sputum, bronchoalveolar lavage fluid, biopsy specimen, or autopsy specimen) or histopathologic evidence (including immunostaining) for RSV in an autopsy specimen. Outcomes of RSV infection were determined at 60 days after the first positive RSV DFA and/or viral culture result. Death from all causes was assessed within 60 days from RSV diagnosis and was attributed to RSV if a persistent or progressive RSV infection with respiratory failure was present at the time of death. Complete response was defined as the resolution of all clinical manifestations of RSV infection with or without microbiological resolution as some patients may shed the virus for a long period of time without evidence of ongoing infection. The isolation of another organism within 30 days before or after the onset of RSV infection was considered as a coinfection. For HSCT recipients, engraftment was defined as an absolute neutrophil count (ANC) of Z500 cells/mL for 3 consecutive days. Neutropenia was defined as ANC < 500/mL and lymphocytopenia was defined as an absolute lymphocyte count <200/ mL. RSV infection was considered to be nosocomial if a patient developed signs and symptoms of respiratory infection Z96 hours after hospitalization.
Data Collection
From the patient medical records, we obtained the following information: demographics, cancer type, immunosuppressive treatment, risk factors for progression from URTI to LRTI, details of any treatment for RSV, and final outcome.
RSV-specific Antiviral Therapy
As described previously, 11 AR was administered at 6 g/d and delivered at 20 mg/mL for 18 h/d with a small particle aerosol generator unit (SPAG-2) using a face mask inside a scavenging tent to prevent environmental contamination. A split, intermittent dosing schedule was also used in some patients with RSV URTI. This method of administration uses the same daily dose of AR as the continuous schedule (6 g/d) but alters the concentration to 60 mg/mL to be given over 2 to 3 hours every 8 hours. The efficacy of antiviral therapy in preventing progression to LRTI was determined according to whether patients had received this therapy at the URTI stage. Antiviral therapy had been initiated at the treating physician's discretion, usually when the RSV DFA and/or viral culture result and/or the results of a chest x-ray and/or computed tomography of the chest became available. Duration of antiviral therapy was also decided by the treating physician and hence varied for each individual (median, 3 d; range, 1 to 11 d).
Some patients were treated with polyclonal IVIG or palivizumab. IVIG was administered every other day for 3 to 5 doses at 500 mg/kg/dose and palivizumab as a single dose at 15 mg/kg intravenously.
Statistical Analyses
Descriptive statistics were used for patient characteristics. Categorical variables were compared using the w 2 test and Fisher exact test and continuous variables were compared using Student t test in univariable analyses. Pr0.05 was considered to be statistically significant. Bivariable logistic regression analyses were used to identify risk factors for progression to LRTI; however, small sample size prohibited a multivariable modeling for this outcome. All statistical analyses were performed with Stata software, version 11 (Stata Corp, College Station, TX).
RESULTS
Patient Characteristics
We identified 59 cases of RSV infections in children with cancer cared for at MD Anderson between January 1, 1998, and December 31, 2009 with an incidence of 0.8 cases per 1000 patient-days. The annual distribution of cases including nosocomial infections is depicted in Figure 1 Majority of cases (43, 73%) were communityacquired. Detailed patient characteristics are described in Table 1 . The median age of patients was 5 years (range, 9 mo to 18 y), and almost half were male (29, 49%). The cancer type in about half of patients was hematologic malignancy (HM) (31, 53%), predominantly acute lymphoblastic leukemia (28, 47%), and 19 (32%) patients had undergone HSCT. Cytotoxic chemotherapy and corticosteroids had been received within 1 month before RSV diagnosis by 45 (76%) and 23 (39%) patients, respectively. A total of 20 (34%) patients had neutropenia, and 14 (24%) patients had lymphocytopenia. At RSV diagnosis, 48 (81%) patients presented with URTI, and 11 (19%) with LRTI. Cough (51, 86%), runny nose (45, 76%), and fever (44, 75%) were the most common symptoms at RSV diagnosis.
Progression to LRTI
Overall, 22 (37%) patients developed LRTI, including 11 who progressed from URTI to LRTI (Table 2) . No significant risk factors for progression to LRTI were identified. However, a trend of higher rate of RSV-LRTI was observed for male sex (odds ratio = 2.57 [0.86-7.62], P = 0.09) and children with lymphocytopenia (odds ratio = 2.95 [0.86-10.12], P = 0.085). The outcomes were significantly different in patients who progressed to LRTI; with a higher requirement of intensive care unit stays, and higher 60-day mortality rate. Of the 22 patients who progressed to LRTI, only 3 (14%) received treatment at the URTI stage. Of the remaining 19 patients who progressed to LRTI, 13 were treated at the LRTI stage.
RSV-specific Antiviral Therapy
Outcomes of RSV infections in children with cancer stratified by any type of antiviral therapy administered at URTI stage is demonstrated in Figure 2 
Mortality
A total of 3 patients died within 60 days of RSV diagnosis and all of them had developed respiratory failure as a result of RSV-LRTI. One of these patients also had bacteremia and fungemia, and another had concomitant herpes simplex virus pneumonia at the time of death. These 3 patients were male who developed nosocomial RSV infections. All of them had an Acute Physiology and Chronic Health Evaluation II Score >15, were neutropenic and lymphocytopenic at the time of first assessment of respiratory symptoms, and had coinfections within 1 month of RSV diagnosis. Two patients had undergone allogeneic HSCT (1 matched related bone marrow transplant and 1 mismatched related peripheral blood stem cell transplant) and one was suffering from HM. None of the 3 patients had been treated at the URTI stage. They all required an intensive care unit stay with mechanical ventilation for respiratory support despite ribavirin therapy at LRTI stage. wAt the time of first assessment of respiratory symptoms at the hospital. zWithin 1 month before and after RSV diagnosis; coinfections included 10 bacteremia (6 coagulase-negative staphylococcus, 1 Stomatococcus species, 1 Enterococcus faecium, 1 Candida krusei, and 2 a-hemolytic streptococcus); 2 CMV reactivations; 2 upper respiratory tract infection (Streptococcus pneumoniae); 2 lower respiratory tract infections (Mycobacterium fortuitum and methicillin-resistant Staphylococcus aureus); 2 cystitis (BK virus); 2 gastrointestinal infections (Clostridium difficile); and 1 soft-tissue infection (coagulase-negative staphylococcus, and Enterococcus species). Five patients had >1 copathogens.
yRibavirin or IVIG or palivizumab (alone or combined). APACHE II score indicates Acute Physiology and Chronic Health Evaluation II Score; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit; LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus; URTI, upper respiratory tract infection.
Because the number of deaths was low, we did not attempt a multivariable analysis to identify predictors of mortality.
HM Versus HSCT
When we compared patients with hematologic malignancies, patients with solid tumors and HSCT recipients, no significant differences in characteristics or outcome of RSV infection were noted (data not shown).
DISCUSSION
Our study includes a large number of children with cancer and RSV infections. We found that 1/3 had pneumonia with 5% mortality rate. Mortality rate was much higher for patients progressing to LRTI (3/22, 14%). No significant risk factors for progression to RSV-LRTI, except for higher trend in males and lymphocytopenic children, were observed. No significant difference in outcomes was observed with respect to antiviral therapy administered at URTI stage. Interestingly, no deaths occurred when children with RSV-LRTI were treated with palivizumab with or without ribavirin.
Overall, 59% of patients with HM and about 32% of HSCT patients developed RSV-LRTI. This finding is consistent with the results of previous studies, which reported progression to LRTI in 8% to 58% of pediatric cancer patients 6,12,13 but up to 100% of pediatric patients with HM. 14 The severity of immunodeficiency plays an important role in increasing the risk of RSV infection, of progression to LRTI, and of RSV-related mortality. Lymphocytopenia 15 has often been identified as a predictor of progression to LRTI, not only in the pediatric population but also in adult HSCT recipients as well as patients with leukemia. 16 Severe RSV infection has been described as more likely in children with cancer who were receiving immunosuppressive chemotherapy. 6, [17] [18] [19] [20] Although neutropenia has not been conclusively established to be an independent risk factor for the development of LRTI or for RSV-related mortality, it may be considered to play a role in the development of coinfections, especially bacterial infections, which may contribute to higher morbidity and mortality. In contrast, more than half of our patients were admitted because of RSV infection with a median length of stay for patients with LRTI of 6 days, which is shorter than that reported in other studies (7 to 19 d). 6, 8, 12, 18 The mortality rate in our cohort of patients was low (5%). This finding is consistent with the results of previous studies in high-risk children with cancer, which report overall mortality rates of 0% to 20%. Mortality rates of up to 50% in patients who progress to LRTI have been reported 6, 12, 17 ; however, we observed a rate of 14% (3 deaths in 22 children with LRTI) which is at the lower end of that reported. 6, 12, 17 High mortality rates have also been reported for children who have undergone HSCT and progressed to LRTI, 5 but most studies including ours had small number of HSCT recipients. RSV infections may follow a more severe course in immunocompromised adult patients than in immunocompromised pediatric patients; in adults, 50% to 80% of patients develop LRTI, and mortality rates may reach 100% when treatment is initiated late in the course of the disease, especially in HSCT recipients. 21 Ribavirin treatment, alone or in combination with immunomodulators, has been shown to prevent progression to LRTI and mortality in adults 22, 23 ; however, its benefit in children has not be demonstrated yet.
Some studies have indicated that RSV-specific antiviral therapy improves outcomes in children with cancer, 5, 13 but those studies included only small numbers of patients and lacked control groups. The efficacy of AR in reducing the severity of RSV infection in high-risk patients has not been established, and no specific recommendations exist on the use of AR in immunocompromised children. Although immunomodulators have been shown to reduce pulmonary viral loads of RSV in immunocompromised animal models, 24, 25 they have demonstrated variable success in pediatric patients. Palivizumab, a humanized RSV-specific monoclonal antibody, has been approved for prophylaxis of severe RSV infection in high-risk children. 26 Palivizumab has been shown to reduce respiratory syncytial viral loads and reduce mortality when used alone or in combination with ribavirin. 6 Polyclonal immunoglobulins have also been studied in HSCT children with LRTI and have been shown to produce modest reductions (9%) in mortality. 8 Although, our data did not show significant differences in the rates of progression to LRTI (30% vs. 39%) and 60-day RSV-associated mortality rate (0% vs. 6%) for patients receiving antiviral therapy at URTI stage compared with those who did not, no deaths were observed in group receiving palivizumab alone or in combination with ribavirin. We observed that children who developed LRTI had significantly better survival rates when treated with ribavirin plus immunomodulators compared with ribavirin alone. A limitation of our study is being retrospective and with small number of patients, hence caution is recommended while interpreting our results.
In summary, ribavirin alone did not show any benefit in reducing LRTI or mortality in children with cancer; however, addition of palivizumab to the treatment regimen may be potentially beneficial, especially for children with LRTI but further studies are needed to establish efficacy.
